Celgene’s Abraxane Recommended for NHS Wales

The Welsh government has recommended Celgene’s Abraxane to treat pancreatic cancer on the National Health Service (NHS) in Wales. Specifically, Abraxane (nab-paclitaxel) has been approved by the All Wales Medicines Strategy Group as an option for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Mark

Continue Reading

NICE Recommends Boehringer’s Cancer Drug, Giotrif

Lung cancer patients in England and Wales could gain access to a new treatment after cost regulators, NICE, have recommended Boehringer Ingelheim’s targeted therapy Giotrif (afatinib). The National Institute for Health and Care Excellence (NICE) has published draft regulatory guidance recommending Giotrif as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC),

Continue Reading

NICE Draft Guidance Rejects First-Line Yervoy for Advanced Melanoma

England and Wales’ cost regulator, NICE, have published draft guidance recommending that Bristol-Myers Squibb’s Yervoy (ipilimumab) should only be used by the National Health Service (NHS) for patients in clinical trials, as current evidence is lacking. The regulatory body has already approved the skin cancer drug as a second-line treatment for advanced malignant melanoma, but

Continue Reading

NICE Halts Second-Line Use of Tarceva

NHS cost regulatory body, NICE, have today published updated draft guidance, proposing to stop backing the second-line use of Tarceva (erlotinib) to treat relapsed non-small cell lung cancer (NSCLC). Following a review of the existing guidance the National Institute for Health and Care Excellence (NICE) has decided that treatment after first-line therapy has failed is

Continue Reading